Zetomipzomib and the PORTOLA Trial: A Transformative Step Forward in Autoimmune Hepatitis (AIH)

Description

This session will present findings from the Phase 2a PORTOLA trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in autoimmune hepatitis. Attendees will hear insights on the study design and clinical outcomes, followed by expert discussion on the potential role of immunoproteasome inhibition in advancing treatment for this challenging disease.

Industry Supporter: Kezar Life Sciences, Inc